|Title:||Method for administering a sustained release ranolanolazine formulation|
|Abstract:||A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.|
|Inventor(s):||Wolff; Andrew A. (San Francisco, CA), Baker; Fiona (Dunfermline, GB), Langridge; John Richard (Wales, GB)|
|Assignee:||CV Therapeutics, Inc. (Palo Alto, CA)|
1. A method for treating a human patient suffering from variant or exercise-induced angina by administering a sustained release pharmaceutical dosage form including at least 50%
by weight ranolazine and an admixture of at least one pH-dependent binder and at least one pH-independent binder wherein the pharmaceutical dosage form is administered in no more than two tablets per dose to the human patient to maintain ranolazine
plasma levels in the human patient of from about 550 to about 7500 ng base/mL for at least 24 hours wherein the dose is administered at a frequency selected from the group consisting of once, twice or three times over 24 hours and wherein the peak to
trough plasma ranolazine level does not exceed 3:1 over a 24 hour period.
2. The method of claim 1 wherein the sustained release pharmaceutical dosage form consists essentially of an admixture of from about 70 to about 80 wt % ranolazine, from about 5 to about 12.5 wt % methacrylic acid copolymer, from about 1 to about 3 wt % hydroxypropyl methylcellulose, microcrystalline cellulose, sodium hydroxide, and magnesium sterate, wherein each compressed tablet includes from about 350 to about 800 mg ranolazine.